Bookmark and Share
Feed icon


chromosome 22q deletion

Parkinson's chromosome deletion linked to other genetic disorders

Researchers, led by BRC-supported Professor Nicholas Wood, UCL Institute of Neurology, have made a breakthrough in their understanding of Parkinson’s disease after they discovered a chromosome deletion linked to Parkinson’s disease and other genetic disorders. More...

Prof John Hardy

Prof John Hardy is the first UK winner of $3m Breakthrough Prize in Life Sciences

Professor John Hardy (UCL Institute of Neurology) has been awarded the $3 million Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. More...

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.

Successes of Deep Brain Stimulation for patients with Parkinson's disease

15 April 2011

Unit of Functional Neurosurgery team

A team, led by Dr Tom Foltynie, from UCL Institute of Neurology’s Unit of Functional Neurosurgery recently published a study in the Journal of Neurology, Neurosurgery and Psychiatry, highlighting the positive results of Subthalamic Nucleus Deep Brain Stimulation (STN DBS) surgery on patients with Parkinson’s disease. Specifically the study looked at the outcome of 79 consecutive patients who underwent the surgery at the National Hospital of Neurology and Neurosurgery, Queen Square, showing that the surgery was both safe and beneficial to Parkinson’s patients.

The team demonstrated that at their 12 month follow-up visits, patients' symptoms and signs of Parkinson's had improved by 55% compared with their disability at start of the study. These figures compare favourably with all previously published series of STN DBS studies and justify the novel approach used by the researchers – that of “magnetic resonance image guided targeting." This approach allows researchers to ensure that electrodes are placed precisely and accurately using only a single trajectory through each hemisphere of the patient's brain.

Most importantly the team showed that by using this approach, the safety of performing STN DBS at Queen Square is second to none as not a single patient experienced any form of haemorrhage within the brain. An editorial accompanying this paper written by Professor Paul Krack in Grenoble, France described these data as "a new Benchmark in STN DBS".

Acknowledgements: The Unit of Functional Neurosurgery at the UCL-IoN is supported by the Parkinson Appeal and the Edmond J. Safra Philanthropic Foundation

Image: The team at the Unit of Functional Neurosurgery

Media Contact: Alison Brindle

Page last modified on 15 apr 11 15:57